

4 October 2022

s 9(2)(a)

By email: s 9(2)(a)
Ref: H2022012881

Dear s 9(2)(a)

Response to your request for official information

Thank you for your request under the Official Information Act 1982 (the Act) to Manatū Hauora (Ministry of Health) for:

“Can I please request if there has been any consultation or decision on if/when the migraine drug named ubrelvy will be available in New Zealand.”

Medsafe has not received an application for the medicine Ubrelvy, or any other medicine with the active ingredient ubrogepant.

Information on Medsafe medicines approval process is publicly available here:
www.medsafe.govt.nz/Consumers/Safety-of-Medicines/Medsafe-Evaluation-Process.asp

Please note, Medsafe is not the funder of medicines in New Zealand, this is the role of PHARMAC. More info here www.pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/.

If you are experiencing migraines, I recommend you discuss this with your General Practitioner (GP) who is best placed to give treatment advice.

I trust this information fulfils your request. Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any decisions made under this request. The Ombudsman may be contacted by email at: info@ombudsman.parliament.nz or by calling 0800 802 602.

Yours sincerely



Chris James
Group Manager
Medsafe